Eli Lilly to study baricitinib for Covid-19 treatment
The company signed an agreement to add a baricitinib arm in NIAID’s Adaptive COVID-19 Treatment Trial. Credit: Momoneymoproblemz.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more